Search Results
Dec 02, 2025, 18:11 ET Accord Healthcare kündigt Einführung von Denosumab∇ an - zweites Biosimilar im Bereich Knochengesundheit
Vergleich der PK/PD, Wirksamkeit sowie Sicherheit von OSVYRTI und Prolia bei postmenopausalen Frauen mit Osteoporose. Die Ergebnisse der klinischen Studie zeigen, dass OSVYRTI und sein Referenzprodukt Prolia sehr ähnlich sind und keine klinisch bedeutsamen Unterschiede in Bezug auf PK, PD, Sicherheit und
More news about: Accord Healthcare
Dec 02, 2025, 17:56 ET Accord Healthcare、骨健康分野で2番目のバイオシミラー「デノスマブ∇」の発売を発表
OSVYRTIおよびJUBEREQの承認は、第I相試験と主要評価項目を達成した第III相試験の2つの試験結果に基づいています。第I相試験は、健康な成人男性を対象にJUBEREQとXgevaを比較した無作為化二重盲検三群間薬物動態（PK）試験です。本試験では、両製品のPKパラメータが同等であることが示されました。4第III相試験は、閉経後骨粗鬆症の女性を対象に、OSVYRTIとProliaのPK/PD、有効性、安全性を比較した無作為化二重盲検活性対照並行群間多施設共同試験です。臨床試験の結果、OSVYRTIとその参照製品であるProliaは高度に類似しており、PK、PD、安全性、有効性の観点から臨床的に意味のある差異は認められないことが示されました。2、4Accord
More news about: Accord Healthcare
Dec 02, 2025, 17:53 ET Accord Healthcare anuncia o lançamento do Denosumabe∇ - Segundo Biossimilar em Saúde Óssea
produtos.4 O estudo de Fase III foi um estudo randomizado, duplo-cego, controlado por ativo, de braço paralelo, multicêntrico comparando PK/PD, eficácia e segurança do OSVYRTI em relação ao Prolia em mulheres na pós-menopausa com osteoporose. Os resultados do estudo clínico demonstraram que
More news about: Accord Healthcare
Dec 02, 2025, 16:05 ET Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
agent-of-choice and the Ziihera combinations to become the new standard of care for patients with HER2+ first-line metastatic GEA regardless of PD-L1 status. Alongside new analyses from the HERIZON-BTC-01 Phase 2b trial, these presentations highlight the continued impact of our broad zanidatamab
More news about: Jazz Pharmaceuticals plc
Dec 02, 2025, 09:00 ET Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities
program paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor currently in clinical trials for both brain cancer and advanced breast cancer, advancing the PD-L1 degrader program, and for general corporate purposes. The Company expects the net proceeds from the PIPE, combined with the existing cash and cash
More news about: Kazia Therapeutics Limited
Dec 02, 2025, 08:57 ET Tiger Group Offers Assets from Turf Company's Georgia Plant
two-story creel2022 Zhejian Tianzhu textile machinery yarn twister (less than 5 hours of use)Allma/Saurer Technocorder twisterATI PD96 3D precision laser box grader(2) Jacobsen Turfco Met-R-Matic XL topdressers(4) model 920HDE GreensGroomer turf brushes(2)
More news about: Tiger Group
Dec 02, 2025, 08:45 ET Korea University Study Finds Restless Legs Syndrome Linked to Parkinson's Risk--Dopamine Treatment May Be Protective
patients with restless legs syndrome (RLS) face a higher risk of developing Parkinson's disease (PD). In a nationwide cohort of nearly 20,000 people, untreated RLS patients showed approximately double the PD incidence, while dopamine agonist treatment appeared to have a protective effect. The findings
More news about: Korea University College of Medicine
Dec 02, 2025, 04:00 ET Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy
Ib/II CLINCH-2 study evaluating ATG-022 (CLDN18.2 antibody-drug conjugate [ADC]) in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), as well as ATG-022 in combination with pembrolizumab and chemotherapy.
More news about: Antengene Corporation Limited
Dec 02, 2025, 03:00 ET Power Metallic Intercepts 4.40 Meters of 12.18% Cu (14.34% CuEqRec) included within 20.40 Meters of 2.91% Cu (3.58% CuEqRec) in Hole 25-029b at Lion, and Completes the Extension of PN-24-064 to define large off-hole BHEM anomaly
CuPdPt
More news about: Power Metallic Mines Inc.
Dec 02, 2025, 02:00 ET Accord Healthcare Announces Launch of Denosumab∇ - Second Biosimilar in Bone Health
multicenter study comparing PK/PD, efficacy and safety of OSVYRTI to Prolia in postmenopausal women with osteoporosis. The clinical study results demonstrated that OSVYRTI and its reference product, Prolia, are highly similar, and have no clinically meaningful differences in terms of PK, PD, safety and efficacy.2,4About
More news about: Accord Healthcare
Dec 02, 2025, 02:00 ET Accord Healthcare Announces Launch of Denosumab∇ - Second Biosimilar in Bone Health
multicenter study comparing PK/PD, efficacy and safety of OSVYRTI to Prolia in postmenopausal women with osteoporosis. The clinical study results demonstrated that OSVYRTI and its reference product, Prolia, are highly similar, and have no clinically meaningful differences in terms of PK, PD, safety and efficacy.2,4About
More news about: Accord Healthcare
Dec 01, 2025, 17:31 ET Colorectal Cancer Market Set to Expand Throughout Forecast Period (2025-2034) Driven by Increasing Screening Rates and Novel Drug Approvals | DelveInsight
others.Shanghai Henlius Biotech's HLX10 is a novel humanized recombinant monoclonal antibody (mAb) targeting Programmed Cell Death Protein 1 (PD-1), developed independently by Henlius. It shows promise for the treatment of multiple solid tumors, demonstrating improved pharmacokinetic and pharmacodynamic
More news about: DelveInsight Business Research, LLP
Dec 01, 2025, 09:09 ET New Published Article Discusses How to Make Hospitals Age-Friendly for People with Parkinson's
momentum to ensure people with PD receive the best care possible."PD is the second-most common neurodegenerative disease in the United States, and its prevalence is rising in step with an expanding population of older adults. Even among older adults, people with PD face disproportionate risk of
More news about: Parkinson's Foundation
Dec 01, 2025, 08:45 ET Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium
frontline acute myeloid leukemia (AML) patients. Additionally, Actinium is developing Actimab-A as a potential pan tumor therapy in combination with PD-1 checkpoint inhibitors including KEYTRUDA® and OPDIVO® by depleting myeloid derived suppressor cells (MDSCs), which represents
More news about: Actinium Pharmaceuticals, Inc.
Dec 01, 2025, 06:45 ET Blue Moon Metals Reports Significant Development Momentum on its Norwegian Projects
between the current MRE and a historical high-grade intersection recorded in drillhole NUS-DD-14-001, which returned 9.7 metres at 0.93% Cu, 1.35 g/t Pd, 0.28 g/t Au, 0.61 g/t Pt and 11.5 g/t Ag.The drilling will utilize advanced directional techniques to efficiently test the western extent of the
More news about: Blue Moon Metals
Nov 27, 2025, 06:45 ET In-Silico Clinical Trials Market Set to Reach USD 6.39 Billion by 2033 as Pharma and MedTech Accelerate Digital-First Validation, AI Modeling & Virtual Patient Simulations
dosing, predict toxicity, simulate rare disease outcomes, and replicate population variability. AI-augmented quantitative systems pharmacology (QSP), PK/PD modeling, and virtual screening are cutting years off development timelines.Medical Device EvaluationMedical device simulation accounted
More news about: DataM Intelligence 4 Market Research LLP
Nov 27, 2025, 06:30 ET Intratumoral Cancer Therapies Market to Reach USD 630.7 Million by 2033 as Next-Generation Localized Immunotherapies Transform Solid Tumor Treatment
checkpoint inhibitor responsiveness. Some early-stage trials report ORR improvements of 15–30% when intratumoral therapies are combined with anti-PD-1 or anti-CTLA-4 agents.3. Expanding Use of Virally Engineered TherapiesThe success of FDA-approved oncolytic virotherapies has
More news about: DataM Intelligence 4 Market Research LLP
Nov 26, 2025, 23:30 ET SignOff Semiconductors Pvt Ltd. Expands Global Footprint, Launches Israel Sales Office in Partnership with MosaIC Ltd.
communities.Gary Golembo, GM, MosaIC, commented: "We are delighted to partner with SignOff Semiconductors in Israel. Their proven expertise in PD, DFT/ATPG, and full chip design - backed by strong endorsements and accolades from leading global fabless firms - complements the needs of the Israeli
More news about: SignOff Semiconductors
Nov 26, 2025, 12:00 ET GIGABYTE anuncia seus PCs com IA - GIGABYTE AERO X16 e GIGABYTE GAMING A16 agora disponíveis oficialmente
NIM, os usuários podem criar agentes de IA personalizados e otimizar fluxos de trabalho. Com até 14 horas de autonomia de bateria, carregamento rápido PD 3.0 e áudio Dolby Atmos®, ambos os notebooks suportam estilos de vida modernos orientados por IA.O GIGABYTE AERO X16, um PC Copilot+, é projetado
More news about: GIGABYTE
Nov 26, 2025, 11:59 ET POWER ONE CONFIRMS FIRST EVER GOLD DISCOVERY AT PECORS, EXPANDING A MULTI-METAL SYSTEM IN ONE OF CANADA'S PREMIER JURISDICTIONS - ELLIOT LAKE ONTARIO
or resource.Additional confirmed and historical mineralization includes:Nickel, Copper, PGMs – Including 0.33 g/t Pt+Pd+Au, 0.11% Cu, 0.04% Ni over 12 meters in hole P15-23.Rare Earth Elements (REEs) – Stratigraphically aligned with nearby known
More news about: Power One Resources Corp.
Nov 25, 2025, 22:51 ET FDA approves label update for UNLOXCYT™ (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced cutaneous squamous cell carcinoma (aCSCC)
Transplantation (HSCT) before or after being treated with a PD-1/PDL1 blocking antibody. Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefit versus risks of treatment with a PD-1/PD-L1–blocking antibody prior to or after an allogeneic HSCT.Embryo-Fetal
More news about: Sun Pharma
Nov 25, 2025, 10:06 ET Innova Therapeutics to Advance Novel Cancer Treatment with Enci Therapeutics Acquisition
IVT-8086 induces multiple antitumor effects, including potent reduction in tumor burden in primary and metastatic tumors, reduced expression of CD38 and PD-1 in tumor-infiltrating lymphocytes (TILs), inhibition of angiogenesis, and increased interferon gamma (IFNγ) in tumor-associated macrophages (TAMs)
More news about: Innova Therapeutics
Nov 25, 2025, 10:06 ET Innova Therapeutics to Advance Novel Cancer Treatment with Enci Therapeutics Acquisition
IVT-8086 induces multiple antitumor effects, including potent reduction in tumor burden in primary and metastatic tumors, reduced expression of CD38 and PD-1 in tumor-infiltrating lymphocytes (TILs), inhibition of angiogenesis, and increased interferon gamma (IFNγ) in tumor-associated macrophages (TAMs)
More news about: Innova Therapeutics
Nov 25, 2025, 10:06 ET Innova Therapeutics bringt mit der Übernahme von Enci Therapeutics eine neuartige Krebsbehandlung voran
Antitumoreffekte aus, darunter eine starke Verringerung der Tumorlast in primären und metastasierenden Tumoren, eine verringerte Expression von CD38 und PD-1 in tumorinfiltrierenden Lymphozyten (TILs), eine Hemmung der Angiogenese und eine Erhöhung von Interferon gamma (IFNγ) in tumorassoziierten Makrophagen
More news about: Innova Therapeutics
Nov 25, 2025, 10:06 ET Innova Therapeutics fait progresser un nouveau traitement contre le cancer grâce à l'acquisition d'Enci Therapeutics
antitumoraux, y compris une réduction puissante de la charge tumorale dans les tumeurs primaires et métastatiques, une réduction de l'expression de CD38 et de PD-1 dans les lymphocytes infiltrant les tumeurs (TIL), une inhibition de l'angiogenèse et une augmentation de l'interféron gamma (IFNγ) dans les macrophages
More news about: Innova Therapeutics